Filing Details
- Accession Number:
- 0000950170-24-013482
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-09 19:47:01
- Reporting Period:
- 2024-02-09
- Accepted Time:
- 2024-02-09 19:47:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1815442 | Kymera Therapeutics Inc. | KYMR | Biological Products, (No Disgnostic Substances) (2836) | 812992166 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1821198 | Jared Gollob | C/O Kymera Therapeutics, Inc. 200 Arsenal Yards Blvd., Suite 230 Watertown MA 02472 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-09 | 46,137 | $2.08 | 120,846 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-09 | 38,739 | $35.39 | 82,107 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-09 | 7,398 | $36.09 | 74,709 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-02-09 | 46,137 | $0.00 | 46,137 | $2.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 62,883 | 2029-05-22 | No | 4 | M | Direct |
Footnotes
- These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.
Billionaire Hedge Funds
